Acquiring Company
Synocrom™
Acquired Company
Synocrom™
Lower AustriaLower AustriaManufacturingBiotechnologypharmaceuticalsManufacturingBiotechnologypharmaceuticalsDescription
Croma-Pharma is reacquiring Synocrom™, a hyaluronic acid product aimed at treating knee osteoarthritis. This strategic move marks Croma's return to the orthopaedics market, reflecting its historical roots and expertise. Synocrom™ is set to be available to healthcare professionals in the EU and Switzerland from May 2026. This acquisition continues Croma-Pharma's commitment to innovation in medical applications.
Quick answer
Synocrom™ is acquiring Synocrom™, announced April 8, 2026. Synocrom™ is based in Lower Austria, Austria.
- How much did Synocrom™ pay for Synocrom™?
- The deal value was not disclosed.
- Where are Synocrom™ and Synocrom™ based?
- Synocrom™ is based in Lower Austria, Austria. Synocrom™ is based in Lower Austria, Austria.
- Who are the decision-makers at Synocrom™?
- Fundz holds 1 contact at Synocrom™. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in pharmaceuticals and pharmaceuticals
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Anupam Rasayan to acquire majority in Bliss GVS (May 23, 2026)
- Gujarat Themis Biosyn to Acquire MicroBiopharm Japan (May 22, 2026)
- Everis Medical acquires Hood Laboratories for growth (May 20, 2026)
- AP Technologies acquires Blueacre Technology for growth (May 19, 2026)
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Siegfried acquires three drug substance sites (May 1, 2026)
Who to call at Synocrom™, and when
When Synocrom™ changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Synocrom™ raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Synocrom™, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Synocrom™. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Synocrom™ makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Synocrom™?
Synocrom™ was acquired by Synocrom™, based in Lower Austria. The deal was reported on April 8, 2026. Synocrom™ is a hyaluronic acid product designed for the treatment of knee osteoarthritis. It became a leading brand in Europe during its previous marketing period. Synocrom™ is privately held and operates in Manufacturing.
When did Synocrom™ acquire Synocrom™?
Synocrom™'s acquisition of Synocrom™ was reported on April 8, 2026. Croma-Pharma is reacquiring Synocrom™, a hyaluronic acid product aimed at treating knee osteoarthritis. This strategic move marks Croma's return to the orthopaedics market, reflecting its historical roots and expertise. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Synocrom™ do?
Synocrom™ is a hyaluronic acid product designed for the treatment of knee osteoarthritis. It became a leading brand in Europe during its previous marketing period. It is privately held, operating in Manufacturing, and is based in Lower Austria.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.